GNI Group (2160) · InitiativeAdvanced
GYRE’s Acquisition of Cullgen as a Wholly Owned Subsidiary and Transformation into an Integrated Biopharmaceutical Company
First written in FY2025. 8 of 15 entries say "Advanced", first in 2026-03-05. Latest entry: 2026-08-18.
15entries
1years
13from disclosures
How it moved
Same theme, other companies
Transformation into an integrated biopharmaceutical company through making Cullgen a wholly owned subsidiaryA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- FY2026-H1AdvancedAnnual report
「本株式交換は、2026年５月４日（米国時間）付で取引が完了いたしました。」
Cullgenについて、Gyreを完全親会社、Cullgenを完全子会社とする株式交換が2026年5月4日に完了し、完全統合型バイオ医薬品企業化に向けた取引が実行された。 - FY2025First statedAnnual report
「Following completion of the acquisition, Cullgen will become a wholly owned subsidiary of GYRE. The combined company will be a fully integrated biopharmaceutical company based in the United States and China, with capabilities spanning drug discovery, manufacturing and commercialization, and covering multiple therapeutic areas, including inflammatory diseases, cancer and pain.」
CullgenのPulmatrixとのリバースマージャーに代わる選択肢として、GYREがCullgenを買収し、米国・中国を拠点に創薬から製造、商業化までを統合した企業とする計画が示された。